Daiwa Securities Group Inc. Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX)

Daiwa Securities Group Inc. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 4.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,694 shares of the biopharmaceutical company’s stock after buying an additional 1,180 shares during the period. Daiwa Securities Group Inc.’s holdings in Royalty Pharma were worth $730,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Inspire Investing LLC lifted its stake in Royalty Pharma by 175.1% during the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after acquiring an additional 27,701 shares during the period. APG Asset Management US Inc. bought a new position in Royalty Pharma during the fourth quarter valued at approximately $2,100,000. New Century Financial Group LLC purchased a new stake in Royalty Pharma in the first quarter worth approximately $1,091,000. Patient Capital Management LLC bought a new stake in Royalty Pharma in the 4th quarter worth approximately $35,247,000. Finally, S&CO Inc. raised its stake in Royalty Pharma by 31.0% during the 4th quarter. S&CO Inc. now owns 332,110 shares of the biopharmaceutical company’s stock valued at $9,328,000 after buying an additional 78,500 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RPRX has been the subject of several research analyst reports. Morgan Stanley lifted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a research note on Monday, June 3rd. The Goldman Sachs Group increased their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, StockNews.com lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Monday, September 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Trading Up 0.6 %

Shares of NASDAQ:RPRX opened at $27.72 on Monday. The stock has a 50 day moving average of $27.80 and a 200 day moving average of $28.04. The company has a market cap of $16.45 billion, a PE ratio of 20.69, a price-to-earnings-growth ratio of 4.06 and a beta of 0.46. Royalty Pharma plc has a 12-month low of $25.20 and a 12-month high of $31.66. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same period in the prior year, the business posted $0.85 earnings per share. As a group, equities research analysts expect that Royalty Pharma plc will post 4.04 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were paid a $0.21 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. Royalty Pharma’s payout ratio is presently 62.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.